US · Healthcare · Diagnostics & Research
EPS came in at -0.07 against a street estimate of -0.44 — a beat of 84.1%.
Analysts rate Castle Biosciences Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $46.70.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.78% |
| RTW INVESTMENTS, LLC | 9.09% |
| Principal Financial Group Inc | 5.65% |
| Vanguard Capital Management, LLC | 4.01% |
| Acadian Asset Management LLC | 3.01% |
| Allianz Asset Management AG | 2.88% |
| Vanguard Portfolio Management, LLC | 2.75% |
| Summit Partners Public Asset Management, LLC | 2.70% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $102.891 million, up from $83.043 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $102.9 million, up 24% from $83.0 million in Q3 2025. • Nine-month 2026 revenue was $290.1 million, compared | 2026-11-05 |
| Quarterly report · Q2 2026 CASTLE BIOSCIENCES, INC. - FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net Revenues (Q2 2026): $103.5 million (vs. $86.2 million in Q2 2025); Six | 2026-07-30 |
| Results announced · Q3 2026 CASTLE BIOSCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $103.5 million vs. $86.2 million in Q2 2025 (20% increase) • H1 2026 | 2026-07-30 |
| Shareholder vote results · Q2 2026 CASTLE BIOSCIENCES, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 28, 2026 • Total votes cast across proposals: app | 2026-05-29 |
| Quarterly report · Q1 2026 CASTLE BIOSCIENCES, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $83.679 million (down from $87.988 million in Q1 2025, -4.9% dec | 2026-05-06 |
| Results announced · Q2 2026 CASTLE BIOSCIENCES Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $83.7 million (down from $88.0 million in Q1 2025) • Core Revenue Dr | 2026-05-06 |
| Proxy statement · Q2 2026 CASTLE BIOSCIENCES, INC. — 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Derek J. Maetzold (Founder, President & CEO) — Total compensation de | 2026-04-08 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Castle Biosciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.